These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 30971221

  • 1. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH.
    BMC Cancer; 2019 Apr 11; 19(1):341. PubMed ID: 30971221
    [Abstract] [Full Text] [Related]

  • 2. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT.
    Yonsei Med J; 2018 Oct 11; 59(8):930-936. PubMed ID: 30187699
    [Abstract] [Full Text] [Related]

  • 3. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS.
    J Gynecol Oncol; 2017 Nov 11; 28(6):e73. PubMed ID: 28758379
    [Abstract] [Full Text] [Related]

  • 4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 11; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 5. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Chen X.
    Arch Gynecol Obstet; 2017 Feb 11; 295(2):451-458. PubMed ID: 27913927
    [Abstract] [Full Text] [Related]

  • 6. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J, Liu N, Zhang A, Bao X.
    J Obstet Gynaecol Res; 2018 Sep 02; 44(9):1808-1816. PubMed ID: 30019801
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H, Maurer KA, Nutter B, Rose PG.
    Int J Gynecol Cancer; 2015 Jun 02; 25(5):823-9. PubMed ID: 25828750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY.
    Yonsei Med J; 2020 Apr 02; 61(4):284-290. PubMed ID: 32233170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.